ENTX

Entera Bio Ltd. [ENTX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

ENTX Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

ENTX has more than 8 years of cash runway (104 months)

In the last year, shareholders have seen their holdings diluted. Dilution over past year is 21.56%

Top 10 Correlated ETFs

ENTX

Top 10 Correlated Stocks

ENTX

In the News

03:43 16 Apr 2024 ENTX

Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?

Wise investors are placing some biotech stocks on their watchlists this month, as these companies have surged over 160%. With more predicted upside to these companies than we see today, one could book some serious capital appreciation into a portfolio.

10:41 16 Apr 2024 ENTX

Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?

Here is how Entera Bio Ltd. (ENTX) and FibroGen (FGEN) have performed compared to their sector so far this year.

10:11 16 Apr 2024 ENTX

Here's Why You Should Invest in Entera Bio (ENTX) Stock Now

Here, we discuss some reasons why buying Entera Bio (ENTX) stock now may turn out to be a prudent move.

08:30 16 Apr 2024 ENTX

Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

JERUSALEM, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced that it will participate and be available for investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference being held February 13 – 14, 2024 in a virtual format.

08:30 16 Apr 2024 ENTX

Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting

JERUSALEM, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it has been selected to present data for its investigational agent EB613 at the ASBMR 2023 Annual Meeting on October 13-16, 2023 in Vancouver, BC, Canada.

06:57 16 Apr 2024 ENTX

Entera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimates

Entera Bio Ltd. (ENTX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.12.

06:22 16 Apr 2024 ENTX

Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates

Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 16.67% and 86%, respectively, for the quarter ended December 2022.

07:34 16 Apr 2024 ENTX

Entera Bio Ltd. (ENTX) Flat As Market Gains: What You Should Know

Entera Bio Ltd. (ENTX) closed at $0.95 in the latest trading session, marking no change from the prior day.

07:33 16 Apr 2024 ENTX

Entera Bio Ltd. (ENTX) Flat As Market Sinks: What You Should Know

In the latest trading session, Entera Bio Ltd. (ENTX) closed at $0.95, marking no change from the previous day.

09:47 16 Apr 2024 ENTX

New Strong Buy Stocks for December 29th

SPNS, CRS, DHT, DCBO and ENTX have been added to the Zacks Rank #1 (Strong Buy) List on December 29, 2022.

ENTX Financial details

Company Rating

Sell

Market Cap

105.73M

Income

-4.47M

Revenue

Book val./share

0.35

Cash/share

0.37

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

03 May 2024

P/E

-3.85

Forward P/E

-4.08

PEG

0.58

P/S

1564.19

P/B

3.51

P/C

5.96

P/FCF

-3.26

Quick Ratio

3.74

Current Ratio

3.95

Debt / Equity

0.04

LT Debt / Equity

0.02

EPS (TTM)

-0.15

EPS next Y

-0.54

EPS next Q

EPS this Y

-31.11%

EPS next Y

252.25%

EPS next 5Y

-256.56%

EPS last 5Y

-19.2%

Revenue last 5Y

-100%

Revenue Q/Q

EPS Q/Q

-18.64%

SMA20

100%

SMA50

100%

SMA100

100%

Inst Own

8.78%

Inst Trans

0.98%

ROA

-66%

ROE

-63%

ROC

-0.85%

Gross Margin

-15757%

Oper. Margin

-39800%

Profit Margin

-40629%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

0.52-3.35

52W High

52W Low

RSI

Rel Volume

2.74

Avg Volume

182.6K

Volume

499.61K

Perf Week

13.08%

Perf Month

40.45%

Perf Quarter

221.43%

Perf Half Y

197.97%

Beta

1.713

Volatility

0.26%, 0.44%

Prev Close

-12.5%

Price

2.205

Change

-26.5%

ENTX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.02	0.02	0.02	0	0
Net income per share	-0.9	-0.54	-0.47	-0.45	-0.31
Operating cash flow per share	-0.73	-0.57	-0.35	-0.43	-0.25
Free cash flow per share	-0.74	-0.57	-0.35	-0.44	-0.25
Cash per share	1.25	0.47	0.95	0.43	0.38
Book value per share	0.98	0.36	0.86	0.41	0.36
Tangible book value per share	0.93	0.33	0.86	0.41	0.36
Share holders equity per share	0.98	0.36	0.86	0.41	0.36
Interest debt per share	0.03	0.02	0.01	-0.9	0.01
Market cap	25.99M	19.89M	73.7M	21.03M	17.4M
Enterprise value	11.11M	11.73M	49.11M	8.81M	6.78M
P/E ratio	-2.39	-1.99	-6.05	-1.61	-1.96
Price to sales ratio	110.14	54.49	129.07	156.94	0
POCF ratio	-2.91	-1.91	-8.13	-1.68	-2.38
PFCF ratio	-2.9	-1.9	-8.12	-1.68	-2.38
P/B Ratio	2.18	2.98	3.27	1.79	1.68
PTB ratio	2.18	2.98	3.27	1.79	1.68
EV to sales	47.07	32.14	86	65.76	0
Enterprise value over EBITDA	-0.99	-1.05	-4.04	-0.68	-0.76
EV to operating cash flow	-1.25	-1.13	-5.42	-0.71	-0.93
EV to free cash flow	-1.24	-1.12	-5.41	-0.7	-0.92
Earnings yield	-0.42	-0.5	-0.17	-0.62	-0.51
Free cash flow yield	-0.34	-0.53	-0.12	-0.6	-0.42
Debt to equity	0.03	0.06	0.01	0.01	0.04
Debt to assets	0.02	0.04	0.01	0.01	0.03
Net debt to EBITDA	1.33	0.73	2.02	0.94	1.2
Current ratio	3.41	2.78	8.01	9.58	10.32
Interest coverage	-136.36	-397.61	-421.28	0.5	0
Income quality	0.83	1.04	0.74	0.96	0.82
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	18.14	13.4	9.96	54.13	0
Research and developement to revenue	30.5	17.53	11.86	43.64	0
Intangibles to total assets	0.04	0.06	0	0	0
Capex to operating cash flow	0	0.01	0	0	0
Capex to revenue	-0.17	-0.15	-0.03	-0.35	0
Capex to depreciation	-0.17	-0.24	-0.32	-0.73	-0.3
Stock based compensation to revenue	6.28	2.47	3.26	16.77	0
Graham number	4.45	2.1	3.01	2.04	1.57
ROIC	-0.92	-1.48	-0.52	-1.1	-0.81
Return on tangible assets	-0.68	-1.03	-0.47	-1	-0.76
Graham Net	0.88	0.29	0.83	0.39	0.33
Working capital	11.04M	5.84M	22.17M	11.51M	10.17M
Tangible asset value	11.31M	6.06M	22.57M	11.75M	10.39M
Net current asset value	10.85M	5.51M	21.91M	11.48M	9.88M
Invested capital	0.03	0.06	0.01	0.01	0.04
Average receivables	501.5K	397K	349.5K	361.5K	270K
Average payables	403.5K	1.09M	1M	753.5K	712K
Average inventory	103K	-8.5K	-46.5K	-147K	-147K
Days sales outstanding	429.96	516	116.98	1.47K	0
Days payables outstanding	580.52	3.22K	162.44	4.85K	540.98
Days of inventory on hand	132.1	-162.42	0	-1.06K	0
Receivables turnover	0.85	0.71	3.12	0.25	0
Payables turnover	0.63	0.11	2.25	0.08	0.67
Inventory turnover	2.76	-2.25	0	-0.34	0
ROE	-0.91	-1.5	-0.54	-1.11	-0.86
Capex per share	0	0	0	0	0

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	-0.11	0.08	-0.08	-0.08	-0.07
Operating cash flow per share	-0.07	-0.06	-0.05	-0.05	-0.08
Free cash flow per share	-0.07	-0.06	-0.05	-0.05	-0.08
Cash per share	0.43	0.37	0.32	0.26	0.37
Book value per share	0.41	0.35	0.29	0.22	0.35
Tangible book value per share	0.41	0.35	0.29	0.22	0.35
Share holders equity per share	0.41	0.35	0.29	0.22	0.35
Interest debt per share	-0.7	-0.15	0.02	0.01	0.01
Market cap	21.03M	33.42M	24.29M	20.89M	17.82M
Enterprise value	8.81M	22.78M	15.61M	13.71M	7.19M
P/E ratio	-1.64	3.76	-2.61	-2.2	-2.23
Price to sales ratio	1.5K	0	0	0	0
POCF ratio	-10.46	-20.77	-15.58	-13.7	-7.11
PFCF ratio	-10.44	-20.63	-15.57	-13.7	-7.09
P/B Ratio	1.79	3.32	2.95	3.35	1.72
PTB ratio	1.79	3.32	2.95	3.35	1.72
EV to sales	629.52	0	0	0	0
Enterprise value over EBITDA	-2.89	-10.3	-6.74	-5.78	-3.67
EV to operating cash flow	-4.38	-14.16	-10.01	-8.99	-2.87
EV to free cash flow	-4.38	-14.06	-10.01	-8.99	-2.86
Earnings yield	-0.15	0.07	-0.1	-0.11	-0.11
Free cash flow yield	-0.1	-0.05	-0.06	-0.07	-0.14
Debt to equity	0.01	0	0.06	0.06	0.04
Debt to assets	0.01	0	0.04	0.05	0.03
Net debt to EBITDA	4	4.81	3.75	3.03	5.42
Current ratio	9.58	7.61	5.26	3.95	10.32
Interest coverage	0.15	-0.5	0	0	-61.66
Income quality	0.66	0.73	0.67	0.64	1.26
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	124.36	0	0	0	0
Research and developement to revenue	96.5	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0.01	0	0	0
Capex to revenue	-0.21	0	0	0	0
Capex to depreciation	-0.19	-0.79	-0.07	0.01	-0.37
Stock based compensation to revenue	34.07	0	0	0	0
Graham number	1.01	0.78	0.72	0.63	0.73
ROIC	-0.29	-0.22	-0.51	-0.34	-0.18
Return on tangible assets	-0.24	0.19	-0.22	-0.28	-0.17
Graham Net	0.39	0.32	0.25	0.18	0.32
Working capital	11.51M	9.88M	7.95M	5.99M	10.17M
Tangible asset value	11.75M	10.08M	8.23M	6.24M	10.39M
Net current asset value	11.48M	9.85M	7.6M	5.69M	9.88M
Invested capital	0.01	0	0.06	0.06	0.04
Average receivables	239.5K	464K	355.5K	14.5K	0
Average payables	215K	755.5K	867K	402K	323.5K
Average inventory	0.5	-326.5K	-178.5K	148K	0
Days sales outstanding	1.58K	0	0	0	0
Days payables outstanding	191.25	60.79	1.44K	3.63K	574.62
Days of inventory on hand	0	-26.57	1.78K	0	0
Receivables turnover	0.06	0	0	0	0
Payables turnover	0.47	1.48	0.06	0.02	0.16
Inventory turnover	0	-3.39	0.05	0	0
ROE	-0.27	0.22	-0.28	-0.38	-0.19
Capex per share	0	0	0	0	0

ENTX Frequently Asked Questions

What is Entera Bio Ltd. stock symbol ?

Entera Bio Ltd. is a IL stock and trading under the symbol ENTX

What is Entera Bio Ltd. stock quote today ?

Entera Bio Ltd. stock price is $2.205 today.

Is Entera Bio Ltd. stock public?

Yes, Entera Bio Ltd. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 182.6K
Market Capitalization 105.73M
Employee 17
CEO Ms. Miranda J. Toledano M.B.A.
Headquarters Jerusalem,IL
IPO Date 2018-06-28
Website https://www.enterabio.com

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.